After-Hours Earnings Report for June 17, 2025 : LZB, VTGN, XAIR

La-Z-Boy (LZB), VistaGen Therapeutics (VTGN), and Beyond Air (XAIR) are scheduled to report earnings after hours on June 17, 2025. LZB's EPS is expected to decrease by 2.11% year-over-year, while VTGN's EPS is projected to decrease by 108.00% year-over-year, and XAIR's EPS is expected to increase 61.11% year-over-year. LZB's P/E ratio is below the industry average, while VTGN's and XAIR's are negative and also below the industry average.

Analysis

Upcoming earnings reports on June 17, 2025, present varied outlooks for La-Z-Boy Incorporated (LZB), VistaGen Therapeutics, Inc. (VTGN), and Beyond Air, Inc. (XAIR). La-Z-Boy is anticipated to report an earnings per share (EPS) of $0.93, a modest 2.11% decrease year-over-year; however, the company has a track record of meeting analyst expectations once and exceeding them in the other three quarters of the past year, and its 2025 price-to-earnings (P/E) ratio of 13.24 sits below the industry average of 15.00. In contrast, VistaGen Therapeutics is projected to report a substantial 108.00% year-over-year decrease in EPS to $-0.52, following a miss on consensus earnings in the third calendar quarter of 2024 by -5%, and its 2025 P/E ratio is negative at -1.35 against an industry P/E of 1.20. Beyond Air, another biomedical company, is expected to show a significant 61.11% year-over-year improvement in EPS to $-0.14, having consistently beaten analyst expectations every quarter over the past year, including a notable 16.67% beat in the fourth calendar quarter, though its 2025 P/E ratio remains negative at -0.23.

Key Decisions for Investors

• Investors in La-Z-Boy should monitor if its earnings report surpasses the modest decline forecast, as its historical performance of beating expectations and relatively low P/E ratio could signal undervaluation if positive trends continue.
• Given VistaGen Therapeutics' sharply negative EPS outlook, recent earnings miss, and significantly negative P/E ratio compared to its industry, extreme caution is advised, with the upcoming report pivotal for assessing any turnaround viability.
• For Beyond Air, the anticipated EPS improvement and consistent earnings beats suggest investors should watch for confirmation of this positive trajectory towards reduced losses, which could indicate progress towards profitability despite its current negative P/E.